Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide.
This study reports the cardiovascular and renal actions of a novel and newly synthesized 27-amino acid peptide termed vasonatrin peptide (VNP). VNP is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). This synthetic peptide possesses the 22-amino acid structure of CNP, which is a cardiovascular selective peptide of endothelial origin and is structurally related to ANP. VNP also possesses the five-amino acid COOH terminus of ANP. The current study demonstrates both in vitro and in vivo that VNP possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP.
Wei
C M
CM
Cardiorenal Research Laboratory, Mayo Clinic and Foundation, Rochester, Minnesota 55905.
Kim
C H
CH
Miller
V M
VM
Burnett
J C
JC
D000595:Amino Acid Sequence; D000818:Animals; D001158:Arteries / Q000187:drug effects / Q000502:physiology; D009320:Atrial Natriuretic Factor / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects*; D006152:Cyclic GMP / Q000097:blood; D004285:Dogs; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D066298:In Vitro Techniques; D007537:Isometric Contraction / Q000187:drug effects; D008969:Molecular Sequence Data; D009126:Muscle Relaxation / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000502:physiology*; D020098:Natriuretic Peptide, C-Type; D009419:Nerve Tissue Proteins / Q000737:chemistry / Q000494:pharmacology*; D011487:Protein Conformation; D051381:Rats; D017208:Rats, Wistar; D013329:Structure-Activity Relationship; D014680:Veins / Q000187:drug effects / Q000502:physiology
D009419:Nerve Tissue Proteins; D020098:Natriuretic Peptide, C-Type; C068986:ventricular natriuretic peptide, eel; D009320:Atrial Natriuretic Factor; D006152:Cyclic GMP